Emerging Markets Pricing Strategy

In today’s global market, life science companies worldwide face challenges such as increased austerity measures, unfamiliar emerging markets payers and governments, greater emphasis on health economics and regulatory reforms.

To address these challenges, many companies are turning to integrated teams that include health economics, comparative effectiveness research and market access alongside pricing functions.  The added focus to develop a presence in emerging markets creates new pricing challenges, especially when facing an unfamiliar market with unique regulatory and access issues. Continue reading

Clinical Research in Asia: Factors to Consider

Access to treatment-naïve patients spurs companies to look beyond the borders of their own countries.  Top markets such as the United States are home to hundreds of millions of patients, but the clinical trial market has been saturated with thousands of protocols targeting fewer and fewer treatment-naïve patients.  As a result, companies have chosen to move outside their country borders to find both less-saturated clinical trial markets and more potential trial subjects. Continue reading

Pricing Troubles in India: Compulsory Licensing on the Subcontinent

Jacob Presson, pharmaceutical market access researcher
By Jacob Presson,
Senior Research Analyst

Fresh news out of India this week is likely to add to pharmaceutical companies’ concerns about pricing and sales in emerging markets.  Despite indications in February that compulsory licensing may be coming to an end, on March 18, BDR Pharmaceuticals applied for a compulsory license on dasatinib, an oncology product sold by Bristol-Myers Squibb.  If granted, the compulsory license would severely undermine BMS’s sales in India by allowing BDR to sell a generic product for much lower prices. Continue reading

Pharma Looking Abroad: Emerging Markets Present Big Opportunities in 2013

Jacob Presson, pharmaceutical market access researcher
By Jacob Presson,
Senior Research Analyst

With continuing uncertainty in established markets such as the US and Europe, pharmaceutical companies are looking abroad in pursuit of profits.  While many companies have been laying the groundwork to move into emerging markets for many years now, analysts predict that 2013 will be a big year for the BRIC economies’ role in the pharmaceutical marketplace. However, marketing to these countries (and other emerging markets) requires a solid understanding of each country’s individual economic and regulatory landscape. Continue reading

Consider HEOR Team Partnerships with Academia

In a recent study on HEOR teams, we found that accessing quality data for HEOR analysis is a challenge for companies worldwide. As shown in the accompanying Figure, on a scale of 1 to 10 (with 10 being the most difficult), US companies rated accessing quality data a 6.6, on average, while companies operating in emerging markets rated it an 8, on average. Continue reading

Dedicated Patient Adherence Fuels Bigger Budgets

Sarah Ray, regulatory affairs and safety researcher
By Sarah Ray,
Senior Research Analyst

Saying that patient adherence is straightforward is like saying the only thing required to compete at the Olympics is a plane ticket. It’s simply not true. Fostering long-term patient adherence goes beyond the scope of simply getting patients to take their prescribed medications. Successful patient adherence efforts require the implementation of various channels, from traditional print sources to increasingly popular mobile and digital technologies. It also requires a certain amount of ingenuity and creativity. Having a team run patient adherence as a part of their overall duties simply does not allow companies to do the task justice. Continue reading

Understanding the Importance of Mobile Health for Pharma

Mobile health (mHealth) may be the buzzword of today, but this one will not be just another flash in the pan. The importance of Mobile health is that it offers the life sciences industry far-reaching capabilities to connect with various stakeholders – from patients and caregivers to physicians and pharmacists. This connectivity makes mobile health a valuable tool not likely to be dispensed with anytime soon. Projections show the mobile health industry increasing dramatically: research2guidance found that the global smartphone mHealth app market increased by a factor of 7 from 2010 to 2011, reaching $718 million (USD). This growth is predicted to continue. PwC India projects that the mHealth market will be worth $23 billion by 2017. So what is it about mHealth that is going to fundamentally change healthcare? Continue reading

Amid widespread belt tightening, Pharma is hiring in China

As pharmaceutical companies are feeling the economic downturn, many of them are shedding jobs. A FiercePharma article earlier this year pointed out that ten large pharmaceutical companies announced over 25,000 layoffs in 2011 – a figure that doesn’t include job losses at many smaller companies that faced their own reimbursement or capital challenges. Europe, in particular, is looking like it is unlikely to see strong growth in the next several years, meaning many companies will face headwinds to growth in some of their strongest markets. Continue reading